Vertex Pharma Live Stock Price Today, Share Analysis and Chart

Name: Vertex Pharmaceuticals, Inc.: Is Infosys Ltd. worth buying?
Item: Vertex Pharmaceuticals, Inc.
Rating: 2.258138875
Author: Trendlyne DVM scores

Mid-range Performer

about

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, whe...

476.90 7.63 (1.63%)

31.56% Gain from 52W Low

1.0M

XNAS Volume

XNAS 20 Feb, 2026 4:30 PM (EST)

Board Meeting

The next board meeting for Vertex Pharma is on 03 Mar 2026 for the purpose of TD Cowen 46th Annual Health Care Conference See details

Medium Financial Strength

38.9 / 100

Mid Valuation

43.3 / 100

Technically Neutral

59.5 / 100

Mid-range Performer These stocks have average quality, financial and technical momentum, indicating a mid range performer View Similar Embed DVM

531

1Yr Price target upside is 11%

27 analysts

Vertex Pharma Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Vertex Pharma Live Stock Price Today, Share Analysis and Chart

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, whe...

31.56% Gain from 52W Low

SWOT Analysis

Vertex Pharma Live Price Chart